Rezolute, Inc. (NASDAQ:RZLT) Director Wladimir Hogenhuis Purchases 10,000 Shares

Rezolute, Inc. (NASDAQ:RZLT) Director Wladimir Hogenhuis purchased 10,000 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was bought at an average cost of $4.70 per share, for a total transaction of $47,000.00. Following the acquisition, the director now directly owns 77,267 shares in the company, valued at $363,154.90. This trade represents a 14.87 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Rezolute Trading Down 2.2 %

Shares of Rezolute stock opened at $4.53 on Friday. The company’s 50-day moving average price is $4.84 and its 200-day moving average price is $4.90. Rezolute, Inc. has a 12-month low of $1.49 and a 12-month high of $6.19. The company has a market cap of $274.20 million, a price-to-earnings ratio of -3.71 and a beta of 1.10.

Rezolute (NASDAQ:RZLT) last posted its earnings results on Wednesday, February 12th. The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.11. On average, sell-side analysts predict that Rezolute, Inc. will post -0.93 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. Guggenheim reissued a “buy” rating on shares of Rezolute in a research report on Monday, February 10th. HC Wainwright restated a “buy” rating and issued a $14.00 price objective on shares of Rezolute in a research note on Thursday, February 13th. Craig Hallum raised shares of Rezolute to a “strong-buy” rating in a report on Tuesday, February 4th. JMP Securities lifted their target price on shares of Rezolute from $8.00 to $9.00 and gave the stock a “market outperform” rating in a research note on Thursday, February 13th. Finally, Wedbush restated an “outperform” rating and set a $112.00 price target on shares of Rezolute in a research note on Monday, November 4th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $24.38.

Institutional Investors Weigh In On Rezolute

A number of institutional investors and hedge funds have recently made changes to their positions in the business. JPMorgan Chase & Co. purchased a new position in Rezolute during the third quarter worth about $42,000. Alpine Global Management LLC bought a new stake in shares of Rezolute during the 4th quarter valued at about $54,000. MML Investors Services LLC purchased a new position in shares of Rezolute during the third quarter worth about $57,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Rezolute in the third quarter worth approximately $65,000. Finally, Charles Schwab Investment Management Inc. raised its stake in Rezolute by 65.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 22,757 shares of the company’s stock valued at $112,000 after purchasing an additional 9,000 shares in the last quarter. Hedge funds and other institutional investors own 82.97% of the company’s stock.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.